Approval
FDA Approves WILSERDLY Combination
The FDA approved WILSERDLY plus everolimus for eligible adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer following endocrine therapy. In the Phase III evERA study, the combination reduced the risk of progression or death by 62% versus standard endocrine therapy plus everolimus in the ESR1-mutated population. The FDA is reviewing WILSERDLY for adjuvant treatment of early-stage breast cancer, with a decision due November 30, 2026.
Written by Gosset from public sources. Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.